Jazz’s JZP-258 investigational medicine meets key end points in phase 3 narcolepsy trial

This article was originally published here

The phase 3 global, double-blind, placebo-controlled, randomised-withdrawal, multicentre study has assessed the efficacy and safety of JZP-258 in the treatment of cataplexy and excessive daytime sleepiness (EDS) in

The post Jazz’s JZP-258 investigational medicine meets key end points in phase 3 narcolepsy trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply